Shalini Sharp
Shalini Sharp served as the Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of therapies for rare genetic diseases, between 2012 and 2020. Prior to joining Ultragenyx, Ms. Sharp served as the Chief Financial Officer of Agenus Inc., a biotechnology company focused on cancer immunotherapies, where between 2003 and 2006 she served in various finance, corporate development and corporate strategy roles.
Ms. Sharp currently serves as a director of Neurocrine Biosciences, Inc. (since 2020). She previously served on the board of directors of Mirati Therapeutics Inc. from 2021 until its acquisition by Bristol Myers Squibb in January 2024, Sutro Biopharma, Inc. from 2018 to 2023, Precision Biosciences, Inc. from 2018 to May 2022, and then-Panacea Acquisition Corporation from 2020 to February 2021. She also served as a director of Array BioPharma Inc. from 2017 to 2019, Agenus Inc. from 2012 to 2018, as well as TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of tuberculosis drugs, from 2015 to 2022.
Ms. Sharp previously served in strategic planning and as chief of staff to the chairman of the board of directors of Elan Pharmaceuticals during the company’s restructuring, and as a management consultant at McKinsey & Company and an investment banker at Goldman Sachs, specializing in healthcare at both companies.
Ms. Sharp received her M.B.A. and undergraduate degrees from Harvard University.
